Author | Dylann Cohn-Emery


PLK1 Inhibitor, Abiraterone Combo Shows Preliminary Efficacy and Safety in mCRPC

October 22, 2020

In a phase 2 trial, onvansertib, a polo-like kinase 1 inhibitor, combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer who have early abiraterone resistance, demonstrated a decent safety profile across 3 dosing schedules and efficacy in the evaluable arms.

Investigators Tailor TNBC Therapy Using Genomic Alterations

October 21, 2020

In a presentation at the 2020 Lynn Sage Breast Cancer Symposium, Virginia G. Kaklamani, MD, DSc, reviewed the current genomic tools in the triple negative breast cancer landscape that predict response to targeted treatments.

Nobel Prize in Chemistry Goes to Developers of Genome Editing System CRISPR

October 09, 2020

The creation of the CRISPR-Cas9, a novel gene-editing technology used in oncology and other areas of scientific research was the antecedent for Emmanuelle Charpentier, PhD, and Jennifer A. Doudna, PhD, being awarded the 2020 Nobel Prize in Chemistry.